-- PneumoBlast(TM) Reduces Pathology and Lung Fluid Accumulation in 
     Model of COVID-19

FibroGenesis announced today significant efficacy of its PneumoBlast(TM) 
product in an animal model of lung inflammation which resembles COVID-19.  Mice 
immune systems were stimulated to enter hyper-activation mode, which causes 
symptoms similar to COVID-19.  Once COVID-19 simulation was achieved, 
administration of PneumoBlast(TM) resulted in significant reduction in lung 
fluid accumulation.  Additionally, reduction was observed from infiltration of 
inflammatory cells, as well as suppression of chemical mediators such as 
interleukin-6 (IL-6), which are associated with poor survival in COVID-19 
patients.

Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg

In one set of experiments, control-untreated-mice possessed a lung wet weight 
to body weight ratio (LWW/BW) of 3.7 mg/g.  Mice treated with 
lipopolysaccharide; an agent that induces COVID-19-like lung inflammation 
caused an increase of the LWW/BW ratio of 12.5 mg/g.  Administration of bone 
marrow mesenchymal stem cells (BMSCs) to lipopolysaccharide-treated-mice only 
reduced the LWW/BW ratio to 9.9 mg/g.  In strong contrast, PneumoBlast(TM) 
administration significantly reduced the LWW/BW ratio to 5.2 mg/g in 
lipopolysaccharide-treated-mice (p < .001).  PneumoBlast(TM) showed a 37% 
improvement in outcome compared to BMSCs, which was statistically significant 
(p < .005). More importantly, after the introduction of PneumoBlast(TM) 
fibroblast cell therapy, average LWW/BW ratios returned to baseline control 
numbers of healthy lungs, which resulted in no statistical difference between 
recovered lungs and normal/healthy lungs using PneumoBlast(TM).

When the lung inflammation marker interleukin-6 was assessed, control mice 
possessed 532.3 pg/ml of the cytokine, whereas lipopolysaccharide 
administration caused an increase to 4400.1 pg/ml.  Treatment with BMSCs 
resulted in a slight 26% decrease of IL-6 in the 
lipopolysaccharide-treated-mice to 3317.7 pg/ml, whereas PneumoBlast(TM) 
significantly reduced IL-6 by 80% to 896.2 pg/ml, which was highly significant 
(p < .001).  The use of PneumoBlast(TM) resulted in a 54% improvement over 
BMSCs (p < .001).  The introduction of PneumoBlast(TM) cell therapy resulted in 
a reduction of inflammation back to normal/healthy lung levels in just 24 hours.

"This preliminary data is compelling and urgently needs to be translated into 
clinical trials," said Tom Ichim, Ph.D., Chief Scientific Officer of 
FibroGenesis.  "Our studies showed PneumoBlast(TM) therapy significantly 
outperformed BMSCs in all parameters tested.  We have previously obtained FDA 
IND Clearance #18151, for using similar cells to treat degenerative disc 
disease.  Given the promising efficacy data, combined with existing human 
safety data, I strongly believe PneumoBlast(TM) may offer new hope to patients 
suffering from COVID-19 associated lung disease."

"We are excited about this positive outcome and the ability to dramatically 
reduce fluid accumulation in the lungs," said Pete O'Heeron, President and CEO 
of FibroGenesis. "Once again, compared to stem cells, fibroblasts appear to be 
a more robust and potent cell source.  These data also suggest PneumoBlast(TM) 
may possess activity not only related to suppressing inflammation and fluid 
accumulation, but also to regenerating damage the COVID-19 virus causes to 
lungs.  This is the best result we could have hoped for."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company 
developing an innovative solution for chronic disease treatment using human 
dermal fibroblasts. Currently, FibroGenesis holds 200+ U.S. and international 
issued patents/patents pending across a variety of clinical pathways, including 
Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic 
Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded 
entirely by angel investors, FibroGenesis represents the next generation of 
medical advancement in cell therapy. 

Visit www.Fibro-Genesis.com.

Source - FibroGenesis 

CONTACT: Pete O'Heeron, CEO, Pete.OHeeron@Fibro-Genesis.com